These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1762 related items for PubMed ID: 25630513

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V, Cuisset T, Chenu P, Vrolix M, Martinez C, Dens J, Gach O, Boland J, Claeys MJ, Magne J, Barbato E, Wijns W.
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [Abstract] [Full Text] [Related]

  • 4. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G, Rossini R, Lettieri C, Capodanno D, Romano M, Rosiello R, Guagliumi G, Valsecchi O, Gavazzi A, Angiolillo DJ.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):395-405. PubMed ID: 22109961
    [Abstract] [Full Text] [Related]

  • 5. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 6. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun 01; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correlates and outcomes related to periprocedural myocardial injury during percutaneous coronary intervention for chronic total occlusion: Results from a prospective, single center PCI registry.
    Zhang Q, Hu J, Yang ZK, Ding FH, Zhang JS, Du R, Zhu TQ, Shen WF, Kirtane AJ, Zhang RY.
    Catheter Cardiovasc Interv; 2016 Mar 01; 87 Suppl 1():616-23. PubMed ID: 26864270
    [Abstract] [Full Text] [Related]

  • 11. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.
    Coron Artery Dis; 2014 Aug 01; 25(5):405-11. PubMed ID: 24584031
    [Abstract] [Full Text] [Related]

  • 12. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW.
    JACC Cardiovasc Interv; 2013 Dec 01; 6(12):1263-6. PubMed ID: 24239202
    [Abstract] [Full Text] [Related]

  • 13. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.
    Arch Cardiovasc Dis; 2013 Nov 01; 106(11):554-61. PubMed ID: 24231052
    [Abstract] [Full Text] [Related]

  • 14. Impact of Strut Width in Periprocedural Myocardial Infarction: A Propensity-Matched Comparison Between Bioresorbable Scaffolds and the First-Generation Sirolimus-Eluting Stent.
    Kawamoto H, Panoulas VF, Sato K, Miyazaki T, Naganuma T, Sticchi A, Figini F, Latib A, Chieffo A, Carlino M, Montorfano M, Colombo A.
    JACC Cardiovasc Interv; 2015 Jun 01; 8(7):900-9. PubMed ID: 26003020
    [Abstract] [Full Text] [Related]

  • 15. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.
    J Cardiovasc Med (Hagerstown); 2009 Mar 01; 10(3):245-51. PubMed ID: 19262211
    [Abstract] [Full Text] [Related]

  • 16. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
    Cassese S, De Luca G, Villari B, Berti S, Bellone P, Alfieri A, Montinaro A, Quaranta G, Marraccini P, Piscione F, MATRIX Study Investigators.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):408-16. PubMed ID: 21735531
    [Abstract] [Full Text] [Related]

  • 17. The anatomic- and clinical-based NERS (new risk stratification) score II to predict clinical outcomes after stenting unprotected left main coronary artery disease: results from a multicenter, prospective, registry study.
    Chen SL, Han YL, Zhang YJ, Ye F, Liu HW, Zhang JJ, Xu B, Jiang TM, Zhou YJ, Lv SZ.
    JACC Cardiovasc Interv; 2013 Dec 01; 6(12):1233-41. PubMed ID: 24239199
    [Abstract] [Full Text] [Related]

  • 18. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y, Muramatsu T, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Cho YK, Garcia-Garcia HM, van Boven AJ, Piek JJ, Sabaté M, Helqvist S, Baumbach A, McClean D, de Sousa Almeida M, Wasungu L, Miquel-Hebert K, Dudek D, Chevalier B, Onuma Y, Serruys PW.
    JACC Cardiovasc Interv; 2015 Jul 01; 8(8):1053-1063. PubMed ID: 26205444
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV, Pratiti R, Admane P, Mukherjee D, Mardikar HM.
    Indian Heart J; 2012 Jul 01; 64(5):444-8. PubMed ID: 23102380
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Li W, Fu X, Xue H, Wang Y, Wang X, Zhao Y, Geng W, Yang Z, Gu X, Hao G, Jiang Y, Fan W, Wu W, Li S.
    Cardiovasc Ther; 2013 Aug 01; 31(4):210-4. PubMed ID: 22954393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 89.